scholarly journals Non-Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation in Adult Patients with Sickle Cell Disease

2018 ◽  
Vol 24 (3) ◽  
pp. S59 ◽  
Author(s):  
Santosh Saraf ◽  
Pritesh Rajni Patel ◽  
Karen Sweiss ◽  
Annie Oh ◽  
Matthew Koshy ◽  
...  
Keyword(s):  
Stem Cell ◽  
Sickle Cell Disease ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Sickle Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Adult Patients ◽  
Cell Disease ◽  
Blood Stem Cell Transplantation

Comparable 2-Year-Overall and Progression Free Survival Among Unrelated Cord Blood Transplantation, Unrelated Bone Marrow Transplantation, and Related Peripheral Blood Stem Cell Transplantation In Adult Patients With Standard-Risk Hematological Diseases; A Single Center Retrospective Analysis

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3400-3400
Author(s):  
Aya Nishida ◽  
Daisuke Kaji ◽  
Hikari Ota ◽  
Kazuya Ishiwata ◽  
Masanori Tsuji ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cord Blood ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Adult Patients ◽  
Hematological Diseases ◽  
Standard Risk ◽  
Blood Stem Cell Transplantation

Abstract Comparable 2-year overall and progression free survival among unrelated cord blood, unrelated bone marrow, and related peripheral blood stem cell transplantation in adult patients with standard-risk hematological diseases; A single center retrospective analysis Background Cord blood has become one of the major alternative donor sources for those who lack identical related donors in recent years. In Japan, an annual number of unrelated cord blood transplantation (uCBT) has been increasing and it reached 1179 cases in 2012, which is comparable to those of unrelated bone marrow transplantation (uBMT) and related peripheral blood stem cell transplantation (rPBSCT). So far, there is still limited data available on the comparative outcomes of adult standard risk patients receiving uCBT, uBMT and rPBSCT. Objectiv and method To compare the outcome of uCBT with those of uBMT and rPBSCT for adult patients with standard-risk hematological diseases, we retrospectively reviewed medical records of 142 patients with standard risk hematological diseases who underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Toranomon Hospital from Jan 2005 to December 2011. The definition of standard risk disease is severe aplastic anemia (SAA), myelodysplastic syndrome (MDS) in refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), and refractory cytopenia with multilineage dysplasia (RCMD), acute leukemia in complete remission (CR) 1 or 2, chronic myeloid leukemia in chronic phase, non-Hodgkin lymphoma (NHL) in CR, and adult T-cell leukemia/lymphoma (ATL) in CR. Patients with active infection were excluded. Result The median follow-up day of survivors was 654 (19-2745). The characteristics of patients are summarized in Table 1. Forty-six patients performed uCBT, 66 did uBMT, and 30 did rPBSCT. The median age of the patients was 50 years (range, 16-70). There were more elderly patients in uCBT group than uBMT and rPBSCT groups (p=0.009). Cumulative incidence of neutrophil recovery at 50 days after transplantation was lowest in uCBT group and highest in rPBSCT group (uCBT= 87.1%, uBMT= 94.7%, rPBSCT=100%; P<0.001). Among 9 patients who did not engraft after uCBT, 6 achieved engraftment following 2nd uCBT. The cumulative incidence of grade II-IV acute graft-versus-host disease was comparable in three groups (uCBT= 43.7%, uBMT= 52.7%, rPBSCT=46.7%, P=0.57). Overall survival (OS) (uCBT=66.4%, uBMT=69.7%, rPBSCT=69.8%, P=0.73)(Figure 1), disease free survival (DFS) (uCBT=63.0%, uBMT=63.7%, rPBSCT=63.2%, P=0.82), relapse rate (uCBT=14.8%, uBMT=14.7%, rPBSCT=20.2%, P=0.67), and treatment related mortality (TRM) (uCBT=19.6%, uBMT=21.6%, rPBSCT=16.7%, P=0.52) at 2 years were all comparable among 3 groups. Conclusion Clinical outcomes of uCBT, uBMT and rPBSCT groups for adult standard-risk hematological diseases were comparable. Early death is prominent in uCBT, but the increase of late relapse and GVHD-related complications in rPBSCT offset it. Although immune cells in CB are primarily immature, comparable incidence of relapse with other donor sources indicate sufficient anti-tumor effect of uCB for longterm. uCB can now be considered as a promising donor source almost equivalent to uBM or rPB for adult standard-risk hematological diseases. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Sickle Cell Anemia and Comorbid Leg Ulcer Treated With Curative Peripheral Blood Stem Cell Transplantation

2017 ◽  
Vol 16 (1) ◽  
pp. 56-59 ◽  
Author(s):  
Joseph L. Connor ◽  
Caterina P. Minniti ◽  
John F. Tisdale ◽  
Matthew M. Hsieh
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Leg Ulcers ◽  
Blood Stem Cell Transplantation

Allogeneic bone marrow transplantation or peripheral blood stem cell transplantation (PBSCT) are the only curative therapies for patients with sickle cell disease (SCD). Once the patients have successfully undergone transplantation and engrafted, the hallmark of hemolytic anemia resolves, and normal hemoglobin levels are achieved. Some transplant protocols exclude patients with open wounds, including leg ulcers, because of infection risks associated with transplantation and long-term immunosuppression required to prevent graft-versus-host disease. Recalcitrant and recurrent leg ulcers are a serious complication of SCD and a determinant of morbidity. Here, we report the case of a 37-year-old man with sickle cell anemia and a chronic leg ulcer, who underwent PBSCT, engrafted successfully, and then had complete healing of his ulcer 16 months posttransplant.

Sign in / Sign up

Export Citation Format

Share Document